This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: August 16, 2006
Last updated: November 1, 2016
Last verified: November 2016
This study will assess the efficacy, safety and tolerability of increasing doses of GK Activator (2) in patients with type 2 diabetes whose condition has not been optimally controlled with one previous oral antihyperglycemic agent. After a 2 week washout from their previous antidiabetic therapy, patients will receive GK Activator (2) orally, twice a day for 12 weeks, at increasing doses of 25mg bid to 200mg bid; doses will be titrated to achieve a target fasting glucose level (FPG) of <100mg/dL. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

Condition Intervention Phase
Diabetes Mellitus Type 2 Drug: GK Activator (2) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of patients at each dose who achieve FPG <100mg/dL. [ Time Frame: Throughout study ]

Secondary Outcome Measures:
  • Mean change in HbA1c and FPG from baseline to endpoint; absolute/relative changes in lipid profile. [ Time Frame: At intervals throughout study ]
  • AEs, laboratory parameters. [ Time Frame: Throughout study ]

Enrollment: 127
Study Start Date: July 2006
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: GK Activator (2)
25-200mg po bid for 20 weeks
Experimental: 2 Drug: GK Activator (2)
25-200mg po bid for 20 weeks
Experimental: 3 Drug: GK Activator (2)
25-200mg po bid for 20 weeks
Experimental: 4 Drug: GK Activator (2)
25-200mg po bid for 20 weeks
Experimental: 5 Drug: GK Activator (2)
25-200mg po bid for 20 weeks


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, 18-75 years of age;
  • type 2 diabetes mellitus treated with one oral antihyperglycemic agent for >=3 months prior to screening.

Exclusion Criteria:

  • type 1 diabetes mellitus;
  • treatment with insulin, PPAR agonists or systemic corticosteroids during the 3 months prior to screening;
  • women who are pregnant, breast-feeding or not using adequate contraceptive methods.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00366379

United States, Arizona
Chandler, Arizona, United States, 85225
United States, Florida
Oviedo, Florida, United States, 32765
United States, Idaho
Nampa, Idaho, United States, 83687
United States, Indiana
Evansville, Indiana, United States, 47714
United States, Montana
Butte, Montana, United States, 59701
United States, Ohio
Canton, Ohio, United States, 44718
United States, Oregon
Portland, Oregon, United States, 97239
United States, South Carolina
Greer, South Carolina, United States, 29651
United States, Texas
Midland, Texas, United States, 79707
United States, Virginia
Richmond, Virginia, United States, 23249
Tallinn, Estonia, 10138
Tartu, Estonia, 50406
Tartu, Estonia, 50708
Tartu, Estonia, 51014
Jelgava, Latvia, 3001
Riga, Latvia, 1002
Riga, Latvia, 1038
Chihuahua, Mexico, 31238
Guadalajara, Mexico, 44340
Guadalajara, Mexico, 44650
Pachuca, Mexico, 42086
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT00366379     History of Changes
Other Study ID Numbers: BC19800
Study First Received: August 16, 2006
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on September 21, 2017